Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
β
of holders' portfolios
13F filers
1
institution
Market cap
$182.4M
218M shares
52-week range
$0.69 β $3.10
4% from low
Sector
MEASURING & CONTROLLING DEVICES, NEC
Exchange
NASDAQ
CS
Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.
www.quantum-si.comNo one on the platform currently holds QSI.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 117,900 | $91.3K |
No one on the platform has traded QSI yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$QSI https://finance.yahoo.com/healthcare/articles/quantum-si-q2-earnings-call-030402584.html
View on StockTwits β$QSI No obligatory cat tonight. Let me bring out the cookie monster cause I am going to stuff my face with QSI shares until I choke on it!
View on StockTwits β$QSI I think QSI may be making the necessary changes and optimizations to Proteus to meet the requirements of a potential acquirer, with the ultimate goal of selling the company rather than launching the product independently. Of course, they couldnβt publicly say that while negotiations are taking place behind closed doors. This theory becomes even more interesting when you factor in the 20% workforce reduction they announced. Cutting the workforce while preparing to launch an entirely new product doesnβt exactly sound like a company gearing up for a major commercial rollout. And thereβs still been no word on who purchased those 30 million shares in July 2025. Maybe just a wishful thinking on my part. I think this conference call was designed to demoralize retail investors,and they succeeded!
View on StockTwits β$QSI I'm afraid of this getting delisted or reverse split. Since this Proteus will launch next year and this is my fear factor. If they could stay above 1$ it would be great.
View on StockTwits β$QSI Even if QSI launches Proteus in Q2 2027 as theyβve indicated, it could still take another 2β3 quarters before we see meaningful orders from potential customers and gain real visibility into future revenue. By then, a reverse split may already be necessary to avoid delisting. And an RS could seriously damage the company and investor sentiment. For some reason, I think they are fine- tunning Proteus to meet a customer's requirements, even though hawkins denied that and stated that they are making these changes in Proteus due to their internal analysis and not due to customers demanding it. He ruled out that last point twice when he was asked, as if he was trying to say, there is nothing to see here. Which makes me more suspicious. Then, you have 20% reduction in workforce... that does sound like a company preparing to launch a new product to the market. This conference call was designed to destroy retail investors sentiment. They sure succeeded in that.
View on StockTwits β$QSI Q2 '26 Earnings Results & Recap β’ Reported GAAP EPS of -$0.11 up 31.25% YoY β’ Reported revenue of $0.34M down -41.79% YoY
View on StockTwits β$QSI I am surprised that this isn't down 10-15% now. Dead money for the next 9 months.
View on StockTwits β$QSI they have solid institutional ownership
View on StockTwits β$QSI I think there are some very positive developments. Hoping there will be an investor presentation pdf and a YouTube video on these details.
View on StockTwits β$QSI Canβt see a single positive thing in this release. Totally disappointing.
View on StockTwits βRecent $TICKER stream from stocktwits.com β refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1M | -62.5% | $-0.43 | $-0.56β$-0.27 | β | 1 |
| 2027 | $10M | +844.4% | $-0.40 | $-0.51β$-0.25 | β | 1 |
| 2028 | $28M | +191.0% | $-0.31 | $-0.35β$-0.28 | β | 3 |
| 2029 | $66M | +134.0% | $-0.21 | $-0.27β$-0.13 | β | 1 |
Forward consensus Β· growth is YoY vs the prior fiscal-year estimate Β· Fwd P/E at the current price Β· source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-13 | $-0.11 | $-0.11 | +2.9% |
| 2026-05-07 | $-0.12 | $-0.10 | +16.7% |
| 2026-03-03 | $-0.14 | $-0.08 | +42.9% |
| 2025-11-05 | $-0.12 | $-0.17 | -41.7% |
| 2025-08-05 | $-0.16 | $-0.16 | +0.0% |
| 2025-05-15 | $-0.17 | $-0.11 | +35.3% |
| 2025-03-03 | $-0.18 | $-0.18 | +0.0% |
| 2024-11-12 | $-0.21 |
| $-0.18 |
| +14.3% |
| $791M |
| β |
| AUTLAutolus Therapeutics plc | $2.22 | +4.72% | $591M | β |
| DBVTDBV Technologies S.A. | $14.03 | -0.78% | $336M | β |
Source: Financial Modeling Prep Β· peers by sector/industry